培美曲塞联合丝裂霉素治疗晚期难治性乳腺癌的疗效观察被引量：1

导出

摘要目的:观察培美曲塞联合丝裂霉素治疗对蒽环类及紫杉类和吉西他滨、长春瑞滨及铂类等多药耐药后的晚期难治性乳腺癌的疗效及安全性。方法:多药耐药的晚期难治性乳腺癌患者18例,治疗方案:第一天静脉滴注培美曲塞500mg/m2及丝裂霉素6mg/m2,21d为1个周期,治疗2个周期后评价疗效。结果:有效率为27.7%(5/18),疾病控制率为61.1%(11/18),中位疾病进展时间为4.8个月,中位生存时间为11.6个月。Ⅲ～Ⅳ度药物不良反应包括:中性粒细胞减少4例(22.2%),血小板减少1例(5.6%)。结论:培美曲塞联合丝裂霉素治疗对蒽环类及紫杉类和吉西他滨、长春瑞滨及铂类等治疗失败后的晚期难治性乳腺癌患者有较好的疗效,不良反应可以耐受,值得临床进一步研究。

作者廖小莉胡晓桦李永强刘志辉林燕廖思娜

机构地区广西医科大学附属肿瘤医院化疗一科

出处《广西医科大学学报》 CAS 2013年第1期116-118,共3页 Journal of Guangxi Medical University

基金广西科技厅课题资助项目(No.2010gxnsfa013244)

关键词培美曲塞丝裂霉素晚期难治性乳腺癌化学治疗

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献9

1Perez EA. Current management of metastatic breastcancer[J]. Semin Oncol, 1990,26(4 Suppl 12): 1-10.
2徐兵河.蒽环类耐药性乳腺癌的治疗策略[J].中华肿瘤杂志,2007,29(4):241-244. 被引量：85
3Cohen MH,Johnson JR,Wang YC,et al. FDA drug ap-proval summary: pemetr- exed for injection (Alimt) forthe treatment of non-small cell lung cancer[J]. Oncolo-gist,2005 ,10(6):363-368.
4Martin M,Spielmann M,Namer M,et al. Phase II studyof pemetrexed in breastcancer patients pretreated withanthracyclines [ J]. Ann Oncol, 2003 , 14 ( 8 ): 1 246-1 252.
5张玺炜,高洪元,储冬英,赵子仪.培美曲塞联合顺铂方案治疗蒽环类及紫杉类治疗失败的晚期转移性乳腺癌的初步研究[J].中国癌症杂志,2009,19(9):697-700. 被引量：20
6Hortobagyi GN. Mitomycin: its evolving role in thetreatment of breast cancer[J]. Oncology, 1993 , 50 (sup-pl 1):1-8.
7Maisano R, Caristi N?Mare M, et al. Mitomycin C pluscapecitabine (mixe) in anthracycline- and taxane-pre-treated metastatic breast cancer. A multicenter phase IIstudy[J]. Anticancer Res,2007 ,27(4C): 2 871-2 875.
8Schippert C, Warm M, Blohmer JU, et al. Mitomycin Cin combination with vinorelbine in anthracycline- and/ortaxane-pretreated patients with metastatic breast cancer[J]. Onkologie,2012,35(9):500-504.
9Hirai H, Arai T, Okada M,et al. MK-1775 , a smallmolecule Weel inhibitor, enhances anti-tumor efficacyof various DNA-damaging agents? including 5-fluorou-racil. [J]. Cancer Biol Ther, 2010 ,9(7): 514-522.

二级参考文献27

1徐兵河,赵龙妹,袁芃,储大同.多西紫杉醇联合卡培他滨治疗蒽环类药物耐药性晚期乳腺癌的初步临床结果[J].癌症进展,2004,2(1):18-20. 被引量：24
2徐兵河,李维廉,邸立军.诺维本联合顺铂治疗晚期乳腺癌的多中心临床研究[J].中国肿瘤临床,2004,31(23):1340-1342. 被引量：27
3徐兵河,赵龙妹,王佳玉,袁芃.泰索帝联合顺铂治疗31例蒽环类耐药性晚期乳腺癌疗效分析[J].中华肿瘤杂志,2006,28(6):471-473. 被引量：46
4Boyle P,Ferlay J.Cancer incidence and mortality in Europe,2004[J].Annal Oncol,2005,16(3):481-488.
5Kataja V,Castiglione M,on behalf of the ESMO Guidelines Working Group.Locally recurrent or metastatic breast cancer.ESMO clinical recommendations for diagnosis,treatment and follow-up[J].Annal Oncol,2008,19(2):9-11.
6Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].Cancer J Clin,2005,55(2):74-108.
7Spielmann M,Marlin M,Namer M,et al.Activity of pemetrexed (ALIMTA,multitargeted antifolate,LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane:an interim analysis[J].Clin Breast Cancer,2001,2(1):47-51.
8Hanauske AR,Chen V,Paoletti P,et al.Pemetrexed disodium:a novel antifolate clinically active against multiple solid tumors[J].Oncologist,2001,6(4):363-373.
9Vogelzang N J,Ruathoven JJ,Symanowski J,et al.Phase Ⅲ study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma[J].J Clin Oncol,2003,21(14):2636-2644.
10Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with nonsmall cell lung cancer previously treated with chemotherapy[J].J Clin Oncol,2004,22(9):1589-1597.